https://www.pharmaradar360.com/article/pharmaceutical-industry-mobilizes-to-support-response-to-the-ebola-bundibugyo-vi-eede1dc6fd2152e9Pharma Surgeen2026-06-17T06:57:24.000ZPharmaceutical industry mobilizes to support response to the Ebola Bundibugyo virus disease outbreak and calls for a system that enables rapid response and sustained R&D investmenthttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-544b2b5b274f0e83Pharma Surgeen2026-06-17T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-5eaf6ec3074f2c4fPharma Surgeen2026-06-17T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-a68d93ad12a015ccPharma Surgeen2026-06-17T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-556e45ea107d6353Pharma Surgeen2026-06-17T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-4097a1f485ec6e40Pharma Surgeen2026-06-17T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-5dcc5bed4ab61c34Pharma Surgeen2026-06-17T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-0eb131fce2d9fa56Pharma Surgeen2026-06-17T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-03329cb34e762d88Pharma Surgeen2026-06-17T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-announces-launch-of-its-everolimus-tablets-1-mg-generic-of-zortress-78817205320f2bf1Pharma Surgeen2026-06-17T00:00:00.000Znatco announces launch of its everolimus tablets 1 mg generic of zortresshttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-009aa48655f900b6Pharma Surgeen2026-06-17T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-83c64d43583779e6Pharma Surgeen2026-06-17T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-ff8a195b023d8e22Pharma Surgeen2026-06-17T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/adcock-ingram-completes-delisting-from-jse-natco-pharma-acquires-35-75-stake-d13c46315d66dacePharma Surgeen2026-06-17T00:00:00.000Zadcock ingram completes delisting from jse natco pharma acquires 35 75 stakehttps://www.pharmaradar360.com/article/home-page-0ebfda69baebc3d1Pharma Surgeen2026-06-17T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/leveraging-artificial-intelligence-for-clinical-trial-recruitment-and-retention-5ee1c3322a022b97Pharma Surgeen2026-06-16T18:26:45.000ZLeveraging Artificial Intelligence for Clinical Trial Recruitment and Retentionhttps://www.pharmaradar360.com/article/reimagining-the-clinical-research-coordinator-in-the-age-of-ai-a-commentary-0cfa1676440133c3Pharma Surgeen2026-06-16T18:26:29.000ZReimagining the Clinical Research Coordinator in the Age of AI: A Commentaryhttps://www.pharmaradar360.com/article/bridging-the-gap-in-clinical-research-a-theory-driven-site-centric-framework-for-bbf1e714099cc25aPharma Surgeen2026-06-16T18:26:11.000ZBridging the Gap in Clinical Research: A Theory-Driven, Site-Centric Framework for AI Adoption and Literacyhttps://www.pharmaradar360.com/article/implementation-of-ai-for-future-clinical-data-review-a-literature-review-1e5b7efdbcddb5d7Pharma Surgeen2026-06-16T18:25:44.000ZImplementation of AI for Future Clinical Data Review: A Literature Reviewhttps://www.pharmaradar360.com/article/how-ai-and-regulatory-changes-are-advancing-product-development-18a2591986cd11dePharma Surgeen2026-06-16T18:25:29.000ZHow AI and Regulatory Changes are Advancing Product Developmenthttps://www.pharmaradar360.com/article/clinical-research-in-2026-the-rise-of-connected-development-5a237a70d6de4062Pharma Surgeen2026-06-16T18:25:10.000ZClinical Research in 2026: The Rise of Connected Developmenthttps://www.pharmaradar360.com/article/clinical-trials-without-the-traffic-jams-ai-s-role-in-accelerating-discovery-dff6665d3f20e47cPharma Surgeen2026-06-16T18:24:54.000ZClinical Trials Without the Traffic Jams: AI’s Role in Accelerating Discoveryhttps://www.pharmaradar360.com/article/self-service-check-in-serious-back-end-untangling-the-technology-behind-friction-1a0ca4df8f5778f5Pharma Surgeen2026-06-16T18:24:32.000ZSelf-Service Check-In, Serious Back-End: Untangling the Technology Behind Frictionless Clinical Trial Intakehttps://www.pharmaradar360.com/article/building-the-bridge-why-embedding-clinical-research-in-the-patient-journey-is-th-f503ac501a1cbe8bPharma Surgeen2026-06-16T18:24:08.000ZBuilding the Bridge: Why Embedding Clinical Research in the Patient Journey is the Defining Opportunity of This Momenthttps://www.pharmaradar360.com/article/integrating-behavioral-health-support-into-clinical-trial-participant-retention-40d92e531e9a891ePharma Surgeen2026-06-16T18:23:45.000ZIntegrating Behavioral Health Support into Clinical Trial Participant Retention Strategieshttps://www.pharmaradar360.com/article/trilink-opens-gmp-enzyme-manufacturing-facility-enabling-integrated-ivt-supply-f-337208e68730b5a7Pharma Surgeen2026-06-16T16:31:07.000ZTriLink Opens GMP Enzyme Manufacturing Facility, Enabling Integrated IVT Supply from R&D to Commercial Scalehttps://www.pharmaradar360.com/article/oricell-brings-first-pivotal-stage-car-t-in-liver-cancer-f050b3c2b13fe335Pharma Surgeen2026-06-16T16:00:00.000ZOricell brings first pivotal-stage CAR T in liver cancerhttps://www.pharmaradar360.com/article/chinese-challenger-gan-lee-gains-momentum-in-metabolic-disease-cb9184521bee41a7Pharma Surgeen2026-06-16T16:00:00.000ZChinese challenger Gan & Lee gains momentum in metabolic diseasehttps://www.pharmaradar360.com/article/three-deals-in-six-days-everest-builds-late-stage-apac-portfolio-6d51ddb80b9ad1cfPharma Surgeen2026-06-16T16:00:00.000ZThree deals in six days: Everest builds late-stage APAC portfoliohttps://www.pharmaradar360.com/article/longbio-s-lp-003-meets-phase-iii-allergy-endpoints-6d8ac17f0ba0f7f7Pharma Surgeen2026-06-16T16:00:00.000ZLongbio’s LP-003 meets phase III allergy endpointshttps://www.pharmaradar360.com/article/china-clears-alphamab-s-her2-bispecific-antibody-in-gastric-cancer-3028fc94b14b6236Pharma Surgeen2026-06-16T16:00:00.000ZChina clears Alphamab’s HER2 bispecific antibody in gastric cancerhttps://www.pharmaradar360.com/article/ace-inhibitors-be-aware-of-the-distinction-between-bradykinin-and-histamine-medi-fba60c5523e260b4Pharma Surgeen2026-06-16T13:06:19.000ZACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantlyhttps://www.pharmaradar360.com/article/medienmitteilung-europabefragung-2026-bilaterale-vertrage-weiterhin-breit-abgest-6ca0da48f2d1f702Pharma Surgeen2026-06-16T12:34:59.000ZMedienmitteilung: Europabefragung 2026: Bilaterale Verträge weiterhin breit abgestützthttps://www.pharmaradar360.com/article/anmat-prohibe-el-transito-interjurisdiccional-de-productos-medicos-de-igma-insum-2b573e36bc5934bdPharma Surgeen2026-06-16T12:02:32.000ZANMAT prohíbe el tránsito interjurisdiccional de productos médicos de IGMA INSUMOS HOSPITALARIOS S.R.L.https://www.pharmaradar360.com/article/adial-pharmaceuticals-expands-executive-leadership-team-and-closes-pipe-financin-1ad3b60ce0359ed9Pharma Surgeen2026-06-16T12:00:18.000ZAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financinghttps://www.pharmaradar360.com/article/allergan-aesthetics-receives-u-s-fda-approval-for-skinvive-by-juvederm-for-the-i-ff0d46c5b7c3468cPharma Surgeen2026-06-16T12:00:00.000ZAllergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearancehttps://www.pharmaradar360.com/article/recordati-celebrates-its-first-100-years-at-triennale-milano-with-an-exhibition-170dbb81436e1ea9Pharma Surgeen2026-06-16T11:12:20.000ZRECORDATI CELEBRATES ITS FIRST 100 YEARS AT TRIENNALE MILANO WITH AN EXHIBITION REVEALING OBJECTS AND IMAGES FROM ITS HISTORICAL ARCHIVE FOR THE FIRST TIMEhttps://www.pharmaradar360.com/article/class-3-medicines-recall-orbit-pharma-limited-cyclizine-lactate-50-mg-ml-solutio-3db2aa216d555492Pharma Surgeen2026-06-16T10:47:38.000ZClass 3 Medicines Recall: Orbit Pharma Limited, Cyclizine Lactate 50 mg/ml Solution for injection, EL(26)A/29https://www.pharmaradar360.com/article/high-level-virtual-meeting-of-african-heads-of-states-governments-and-partners-o-48f48ca064297a5ePharma Surgeen2026-06-16T10:32:03.000ZHigh-Level Virtual Meeting of African Heads of States, Governments and Partners on Ebola Bundibugyo virus disease outbreakhttps://www.pharmaradar360.com/article/invitation-conference-de-presse-resultats-2026-du-barometre-360-de-l-attractivit-127206efbbdd7aacPharma Surgeen2026-06-16T09:33:58.000ZINVITATION CONFERENCE DE PRESSE : Résultats 2026 du baromètre 360° de l’attractivité de la France pour l’industrie pharmaceutiquehttps://www.pharmaradar360.com/article/shopping-week-2026-20-28-2569-10-00-21-00-8-10-24971b1a49c6a770Pharma Surgeen2026-06-16T03:33:50.000Zงานบ้านและสวนแฟร์ Shopping Week 2026 วันที่ 20 – 28 มิถุนายน 2569 เวลา 10.00 – 21. 00 น. ณ ฮอลล์ 8 – 10 อิมแพ็ค เมืองทองธานีhttps://www.pharmaradar360.com/article/anzen-pmda-risk-communications-omeprazole-etc-posted-d300bbe6755b3809Pharma Surgeen2026-06-16T03:00:00.000Z[ANZEN]PMDA Risk Communications: Omeprazole etc. postedhttps://www.pharmaradar360.com/article/anzen-revisions-of-precautions-lithium-carbonate-etc-posted-996db894c3c98ba8Pharma Surgeen2026-06-16T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Lithium carbonate , etc. postedhttps://www.pharmaradar360.com/article/agenda-for-august-2026-pharmacology-and-therapeutics-advisory-committee-ptac-mee-644e494825185e49Pharma Surgeen2026-06-16T02:00:00.000ZAgenda for August 2026 Pharmacology and Therapeutics Advisory Committee (PTAC) meetinghttps://www.pharmaradar360.com/article/do-you-need-to-brush-your-tongue-e3a936a9810f58bdPharma Surgeen2026-06-16T00:00:00.000ZDo You Need to Brush Your Tongue?https://www.pharmaradar360.com/article/proposed-cms-rule-aims-to-close-fixed-combo-drug-loophole-0c07c4f910adab38Pharma Surgeen2026-06-15T16:00:00.000ZProposed CMS rule aims to close fixed combo drug loopholehttps://www.pharmaradar360.com/article/longbio-s-lp-003-meets-phase-iii-allergy-endpoints-f6a98f69f6801fe6Pharma Surgeen2026-06-15T16:00:00.000ZLongbio’s LP-003 meets phase III allergy endpointshttps://www.pharmaradar360.com/article/chinese-challenger-gan-lee-gains-momentum-in-metabolic-disease-853e2201dd8aeb49Pharma Surgeen2026-06-15T16:00:00.000ZChinese challenger Gan & Lee gains momentum in metabolic diseasehttps://www.pharmaradar360.com/article/field-safety-notices-8-12-june-2026-154c047bbd4667e9Pharma Surgeen2026-06-15T14:38:02.000ZField Safety Notices: 8 -12 June 2026https://www.pharmaradar360.com/article/improved-early-warning-systems-needed-to-reduce-medicines-supply-risks-says-abpi-5700e8146413aff2Pharma Surgeen2026-06-15T11:31:58.000ZImproved early warning systems needed to reduce medicines supply risks, says ABPIhttps://www.pharmaradar360.com/article/the-uk-should-seek-to-be-a-european-leader-for-rare-disease-medicine-says-new-re-d06cca08f70f94b2Pharma Surgeen2026-06-15T11:31:58.000ZThe UK should seek to be a European leader for rare disease medicine, says new reporthttps://www.pharmaradar360.com/article/abpi-celebrates-a-month-of-major-investment-commitments-into-uk-life-sciences-23c81d4b841de6ebPharma Surgeen2026-06-15T11:31:58.000ZABPI celebrates a month of major investment commitments into UK life scienceshttps://www.pharmaradar360.com/article/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders-7fe6068d3e756fb9Pharma Surgeen2026-06-15T11:31:57.000ZMedicine levy makes the UK un-investable, say pharma leadershttps://www.pharmaradar360.com/article/are-nhs-patients-keeping-up-with-european-neighbours-on-access-to-new-medicines-ee7e6727b1689572Pharma Surgeen2026-06-15T11:31:57.000ZAre NHS patients keeping up with European neighbours on access to new medicines?https://www.pharmaradar360.com/article/time-to-emphasise-the-economics-in-health-economics-89a4a85efc16c1bdPharma Surgeen2026-06-15T11:31:57.000ZTime to emphasise the economics in health economicshttps://www.pharmaradar360.com/article/latest-disclosure-uk-data-higher-r-d-spend-greater-transparency-and-more-partner-256abf74bd5c3b29Pharma Surgeen2026-06-15T11:31:56.000ZLatest Disclosure UK data: higher R&D spend, greater transparency and more partnership with the NHShttps://www.pharmaradar360.com/article/aptose-presents-safety-response-and-mrd-clinical-data-from-tuscany-phase-1-2-cli-686bd460c0f0050bPharma Surgeen2026-06-15T11:30:00.000ZAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentationhttps://www.pharmaradar360.com/article/uk-medicines-investment-the-case-for-improving-the-uk-commercial-environment-83ef8b2171ffb5dePharma Surgeen2026-06-15T11:01:56.000ZUK medicines investment: the case for improving the UK commercial environmenthttps://www.pharmaradar360.com/article/making-wales-a-destination-for-industry-clinical-trials-and-medical-research-6d7614cafd158bcbPharma Surgeen2026-06-15T11:01:55.000ZMaking Wales a destination for industry clinical trials and medical researchhttps://www.pharmaradar360.com/article/abpi-regulatory-science-symposium-2025-1a9f3c049af492c1Pharma Surgeen2026-06-15T11:01:55.000ZABPI Regulatory Science symposium 2025https://www.pharmaradar360.com/article/why-the-pharmaceutical-industry-needs-nhs-data-to-develop-new-medicines-8d4f7fc7d056463cPharma Surgeen2026-06-15T11:01:55.000ZWhy the pharmaceutical industry needs NHS data to develop new medicineshttps://www.pharmaradar360.com/article/disclosure-uk-2024-new-record-for-transparency-with-nine-in-ten-healthcare-profe-06b0cfb05a1e74c5Pharma Surgeen2026-06-15T11:01:54.000ZDisclosure UK 2024: new record for transparency, with nine in ten healthcare professionals named in databasehttps://www.pharmaradar360.com/article/speedy-anna-is-now-award-winning-91398b5a1e89d633Pharma Surgeen2026-06-15T11:01:54.000ZSpeedy Anna is now award-winninghttps://www.pharmaradar360.com/article/getting-ready-for-the-windsor-framework-ensuring-continuity-of-uk-medicines-supp-86c7e6122e7ba17dPharma Surgeen2026-06-15T11:01:53.000ZGetting ready for the Windsor Framework: ensuring continuity of UK medicines supply beyond 1 January 2025https://www.pharmaradar360.com/article/comparing-new-medicine-availability-across-europe-ecb2451c8a8d2ac8Pharma Surgeen2026-06-15T11:01:53.000ZComparing new medicine availability across Europehttps://www.pharmaradar360.com/article/mrna-technology-navigating-preclinical-research-for-rare-diseases-bc8ecb7d06617d1ePharma Surgeen2026-06-15T11:01:52.000ZmRNA technology: navigating preclinical research for rare diseaseshttps://www.pharmaradar360.com/article/june-s-story-of-sickle-cell-18cf1901f8f23588Pharma Surgeen2026-06-15T11:01:52.000ZJune’s story of sickle cellhttps://www.pharmaradar360.com/article/principles-for-analysis-and-use-of-health-data-by-abpi-members-3125668273c1226ePharma Surgeen2026-06-15T11:01:52.000ZPrinciples for analysis and use of health data by ABPI membershttps://www.pharmaradar360.com/article/mhra-s-new-international-recognition-procedure-irp-how-does-it-shape-up-2c5a3abdf7832876Pharma Surgeen2026-06-15T11:01:51.000ZMHRA’s new International Recognition Procedure (IRP): how does it shape up?https://www.pharmaradar360.com/article/my-sons-have-taught-me-more-than-i-could-ever-teach-them-db8e031147390cbaPharma Surgeen2026-06-15T11:01:51.000ZMy sons have taught me more than I could ever teach themhttps://www.pharmaradar360.com/article/tiziana-life-sciences-announces-purchase-of-shares-by-executive-chairman-53893983f98f086fPharma Surgeen2026-06-15T11:00:00.000ZTiziana Life Sciences Announces Purchase of Shares by Executive Chairmanhttps://www.pharmaradar360.com/article/light-digest-vanilla-53807db27b13040fPharma Surgeen2026-06-15T10:23:07.000ZΑπαγόρευση διακίνησης και διάθεσης του προϊόντος «LIGHT DIGEST Vanilla»https://www.pharmaradar360.com/article/xray-diam-5cm-40x40-ref-24-0460-02921cc6a8b2643fPharma Surgeen2026-06-15T10:20:25.000ZΑνάκληση παρτίδας του προϊόντος «ΤΟΛΥΠΙΑ XRAY DIAM 5CM 40X40» REF 24-0460https://www.pharmaradar360.com/article/when-one-testimony-changes-everything-mariam-soukouna-on-purpose-beyond-the-job-8d7ad8be7b526e0bPharma Surgeen2026-06-15T08:14:21.000ZWhen One Testimony Changes Everything: Mariam Soukouna on Purpose Beyond the Job Titlehttps://www.pharmaradar360.com/article/pfic-colors-making-sense-of-pfic-with-the-pfic-network-39c3dfd722905804Pharma Surgeen2026-06-15T07:37:19.000ZPFIC Colors: Making Sense of PFIC with the PFIC Networkhttps://www.pharmaradar360.com/article/meps-and-partner-organisations-call-for-investments-in-vaccine-r-d-to-support-eu-74d48e3f4e13017dPharma Surgeen2026-06-15T06:59:29.000ZMEPs and partner organisations call for investments in vaccine R&D to support EU and global health security and preparednesshttps://www.pharmaradar360.com/article/bijdragen-2b9f99aaa66dca3aPharma Surgeen2026-06-15T06:49:21.000ZBijdragenhttps://www.pharmaradar360.com/article/e-2026-337211279d2c77cfPharma Surgeen2026-06-15T06:33:47.000ZEκτέλεση προϋπολογισμού ΕΟΦ μηνός Μαϊου 2026https://www.pharmaradar360.com/article/cater-with-petro-s-petro-s-chili-chipstm-c40f07eb3e97a089Pharma Surgeen2026-06-15T00:00:00.000ZCater with Petro's! — Petro's Chili & Chips™https://www.pharmaradar360.com/article/otsuka-pharmaceutical-completes-acquisition-of-transcend-therapeutics-5db67a422f7305b3Pharma Surgeen2026-06-15T00:00:00.000ZOtsuka Pharmaceutical Completes Acquisition of Transcend Therapeuticshttps://www.pharmaradar360.com/article/which-type-of-sunscreen-is-best-160fca468c92f956Pharma Surgeen2026-06-15T00:00:00.000ZWhich Type of Sunscreen is Best?https://www.pharmaradar360.com/article/cleveland-clinic-expands-access-to-care-with-an-el-salvador-based-representative-51221623b4991881Pharma Surgeen2026-06-15T00:00:00.000ZCleveland Clinic Expands Access to Care with an El Salvador-Based Representativehttps://www.pharmaradar360.com/article/cleveland-clinic-and-ibm-forum-highlights-advancements-in-ai-and-quantum-computi-4b62e1bfc077ac16Pharma Surgeen2026-06-15T00:00:00.000ZCleveland Clinic and IBM Forum Highlights Advancements in AI and Quantum Computing for Healthcare Researchhttps://www.pharmaradar360.com/article/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-adc-zw19-db3d8bcb01c51eadPharma Surgeen2026-06-14T22:30:56.000ZZymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026